共 50 条
- [21] Advantages of multiple clinical tests for determining the optimum treatment strategy for ER-positive breast cancer NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (07): : 376 - 377
- [22] Advantages of multiple clinical tests for determining the optimum treatment strategy for ER-positive breast cancer Nature Clinical Practice Oncology, 2008, 5 : 376 - 377
- [24] The clinical significance of circulating DSCAM-AS1 in patients with ER-positive breast cancer and construction of its competitive endogenous RNA network Molecular Biology Reports, 2020, 47 : 7685 - 7697
- [28] AgNOR analysis of ER-positive and ER-negative tumor cells in breast cancer PROCEEDINGS OF THE GERMAN SOCIETY FOR PATHOLOGY 82ND MEETING - 1998: SOFT TISSUE TUMORS, 1998, : 470 - 470
- [29] AgNOR analysis of ER-positive and ER-negative cells in breast cancer. EUROPEAN JOURNAL OF HISTOCHEMISTRY, 1996, 40 (04): : 341 - 341
- [30] Exemestane: One part of the chemopreventive spectrum for ER-positive breast cancer BREAST, 2013, 22 (03): : 225 - 237